Form 4: Savara Inc. Executive Anne Erickson Reports Stock and Option Transactions

Savara Inc.'s Chief Business Officer, Anne Erickson, reports the acquisition of 100,000 shares of restricted stock, the withholding of 18,263 shares for tax purposes, and the grant of options to purchase 300,000 shares.

Summary

• Anne Erickson, Chief Business Officer of Savara Inc., reported several transactions involving the company's stock.
• On December 12, 2024, she acquired 100,000 shares of restricted stock units (RSUs) that will vest on December 12, 2026.
• Also on December 12, 2024, she was granted options to purchase 300,000 shares of common stock, which vest quarterly over four years.
• On December 13, 2024, 18,263 shares were withheld by Savara to cover tax liabilities related to the vesting of previous RSUs at a price of $3.21 per share.
• Following these transactions, Ms. Erickson directly owns 434,672 shares of Savara common stock and options to purchase 300,000 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and does not indicate any significant positive or negative developments. The grant of equity suggests confidence in the company's future, but the tax withholding is a neutral event.

Positives

• The grant of 100,000 restricted stock units and 300,000 stock options to a key executive suggests confidence in the company's future performance.
• The vesting schedule of the options and RSUs aligns the executive's interests with the long-term success of the company.

Negatives

• The withholding of 18,263 shares to cover tax liabilities indicates a reduction in the executive's overall shareholding, although this is a standard practice.

Risks

• The vesting of the restricted stock units and options is contingent on the executive's continued service with the company, which introduces a risk of forfeiture if the executive leaves before the vesting dates.

Future Outlook

The document does not contain any specific forward-looking statements or guidance regarding the company's future performance.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical and biotechnology industry. It reflects standard compensation practices for executives in publicly traded companies.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are a common form of compensation for executives in the biotechnology industry, similar to companies like Amgen, Gilead Sciences, and Regeneron.
• The vesting schedules for the options and RSUs are typical, aligning with industry standards for long-term incentive plans.
• The tax withholding of shares is a standard practice across the industry to cover tax liabilities associated with equity compensation.

Stakeholder Impact

• The transactions reported in this document may have a minor positive impact on shareholder sentiment, as they indicate that a key executive is incentivized to contribute to the company's long-term success.
• The vesting of the restricted stock units and options will increase the executive's stake in the company over time.

Key Dates

Keywords

Savara Inc, stock options, restricted stock units, insider trading, executive compensation, Form 4, Anne Erickson, share ownership